18.01.2013 14:20 Uhr, Quelle: Wallstreet online

Today´s Research on Mylan and Watson Pharmaceuticals: One Drug Maker´s Sorrow is Another One´s Joy

LONDON, January 18, 2013 /PRNewswire/ The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 …

Weiterlesen bei Wallstreet online